Ho KY, Thorner MO Therapeutic applications of bromocriptine in endocrine and neurological diseases. Drugs 1988; 36: 67-82
Crosignani PG, Ferrari C Dopaminergic treatments for hyperprolactinaemia. Baillieres Clin Obstet Gynaecol 1990; 4: 441-455
Vance ML, Evans WS, Thorner MO Drugs five years later: bromocriptine. Ann Intern Med 1984; 100: 78-91
Homburg R, West C, Brownell J, Jacobs HS A double-blind study comparing a new non-ergot, long-acting dopamine agonist, CV 205-502, with bromocriptine in women with hyperprolactinaemia. Clin Endocrinol (Oxf) 1990; 32: 565-571
Verhelst JA, Froud AL, Touzel R, Acute and long-term effects of once-daily oral bromocriptine and a new long-acting non-ergot dopamine agonist, quinagolide, in the treatment of hyperprolactinemia: a double-blind study. Acta Endocrinol (Copenh) 1991; 125: 385-391
van der Heijden PFM, de Wit W, Brownell J, Shoemaker J, Rolland R CV 205-502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinaemia. Eur J Obstet Gynecol Reprod Biol 1991; 40: 111-118
Ferrari C, Barbieri C, Caldara R, Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients. J Clin Endocrinol Metab 1986; 63: 941-945
Mattei AM, Ferrari C, Baroldi P, Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients. J Clin Endocrinol Metab 1988; 66: 193-198
European Multicentre Study Group for Cabergoline in Lactation Inhibition. Single dose cabergoline versus bromocriptine in inhibition of puerperal lactation: randomised, double blind, multicentre study. BMJ 1991; 302: 1367-1371
Webster J, Piscitelli G, Polli A, Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study. Clin Endocrinol (Oxf) 1992; 37: 534-541
Ferrari C, Mattei A, Melis GB, Cabergoline: long-acting oral treatment of hyperprolactinemic disorders. J Clin Endocrinol Metab 1989; 68: 1201-1206
Ferrari C, Paracchi A, Mattei AM, de Vincentiis S, D'Alberton A, Crosignani PG Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol (Copenh) 1992; 126: 489-494
Ciccarelli E, Giusti M, Miola C, Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients. J Clin Endocrinol Metab 1989; 69: 725-728
Blackwelder WC “Proving the null hypothesis” in clinical trials. Control Clin Trials 1982; 3: 345-353
Blackwelder WC, Chang MA Sample size graphs for “proving the null hypothesis.” Control Clin Trials 1984; 5: 97-105
Breslow NE, Day NE. Statistical methods in cancer research. Vol. 1. The analysis of case-control studies. Lyon, France: International Agency for Research on Cancer, 1980. (IARC scientific publications no. 32.)
Cox DR, Snell EJ. The analysis of binary data. 2nd ed. London: Chapman & Hall, 1989.
Cutler SJ, Ederer F Maximum utilization of the life table method in analyzing survival. J Chronic Dis 1958; 8: 699-712
